SCHEMBL13909027

SCHEMBL13909027

Cc1ccc(CNc2ccc(Cl)cc2C(=O)O)o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ GAA P10253 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ PPARG P37231 1/20 0.42
▸ PPARA Q07869 1/20 0.42
▸ SERPINE1 P05121 1/20 0.42
▸ TP53 P04637 2/20 0.42
▸ ACLY P53396 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13909025 0.87 ALDH1A1 (0.49) KDM4ESMN1; SMN2LMNAHTTGAA
SCHEMBL15419642 0.76 HSD17B10 (0.55) KDM4EHSD17B10GAAMAPTCA1
SCHEMBL1397659 0.75 KDM4E (0.63) KDM4EHSD17B10SMN1; SMN2HTTRAB9A
SCHEMBL2385151 0.75 NPC1 (0.53) KDM4EHSD17B10SMN1; SMN2LMNANPC1
SCHEMBL3808424 0.75 GAA (0.62) KDM4EHSD17B10GAAMAPTCA9
SCHEMBL15818589 0.74 KDM4C (0.63) KDM4E
SCHEMBL15639856 0.73 KDM4E (0.59) KDM4EHSD17B10SMN1; SMN2RAB9AGAA
SCHEMBL2475653 0.72 KDM4E (0.58) KDM4EHSD17B10SMN1; SMN2KCNH2CA1
SCHEMBL27327673 0.72 HSD17B2 (0.50) KDM4EHSD17B10NPC1RAB9AGAA
SCHEMBL10820458 0.71 KMT2A (0.60) KDM4EHSD17B10SMN1; SMN2KCNH2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090060968-A1 INHIBITORS OF PHOSPHATASES SAUNDERS JEFFREY O 2009-03-05 — — US disclosed
US-20090060968-A1 INHIBITORS OF PHOSPHATASES SAUNDERS JEFFREY O 2009-03-05 — — US disclosed
US-7439249-B2 Inhibitors of phosphatases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-10-21 — — US disclosed
US-7439249-B2 Inhibitors of phosphatases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060968-A1 INHIBITORS OF PHOSPHATASES PPM1G, PPM1A, PPM1F KDM4E 1488/4885HSD17B10 2160/4885SMN1; SMN2 3825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback